- Home
- GILT vs AVTX Comparison
GILT vs AVTX Comparison
Compare GILT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILT | AVTX |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 982.5M |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GILT | AVTX |
|---|---|---|
| Price | $10.01 | $19.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $19.00 | ★ $40.57 |
| AVG Volume (30 Days) | 580.1K | ★ 718.3K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $15.06 | N/A |
| Revenue Next Year | $11.72 | N/A |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $9.50 | $9.54 |
| 52 Week High | $20.99 | $24.27 |
Technical Indicators
Market Signals| Indicator | GILT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 49.22 |
| Support Level | N/A | $18.88 |
| Resistance Level | $12.24 | $20.60 |
| Average True Range (ATR) | 0.35 | 0.82 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 19.78 | 33.02 |
Price Performance
Historical ComparisonAbout GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.